Search
Tedizolid phosphate
go.drugbank.com/drugs/DB09042ApprovedThis product is currently available as both an oral tablet and as a powder for intravenous injection.[L11232] … [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesDosulepin
go.drugbank.com/drugs/DB09167ApprovedInvestigationalDosulepin (INN, BAN) formerly known as dothiepin (USAN), is a tricyclic antidepressant with anxiolytic properties that is used in several European and South Asian countries, as well as Australia, South … Dosulepsin is a thio derivative of [DB00321] with a similar efficacy to that of [DB00321], and also exhibits anticholinergic, antihistamine and central sedative properties [L882].
Celiprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnIt is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. … In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome.
Drotaverine
go.drugbank.com/drugs/DB06751ApprovedWithdrawn[A231619] Drotaverine is not approved by the FDA, European Medicines Agency, or Health Canada. It is approved for use in Thailand as oral tablets or intramuscular injections.[L22689] … [A231619] It is a benzylisoquinoline derivative that is structurally related to [papaverine], although it displays more potent antispasmodic activities than papaverine.
Ibrexafungerp
go.drugbank.com/drugs/DB12471ApprovedIbrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast … [A235414,L34349] Ibrexafungerp was granted FDA approval on 1 June 2021.[L34349]
Synonyms: enfumafungin derivative B-(1,3)-D-glucan synthestis inhibitorFLT190
go.drugbank.com/drugs/DB18420InvestigationalFLT190 is a recombinant adeno-associated viral vector serotype S3 containing DNA encoding for human alpha-galactosidase A.
Recanaclotide
go.drugbank.com/drugs/DB15417InvestigationalRecanaclotide is under investigation in clinical trial NCT01712412 (Phase 2a Study of IW-9179 to Treat Functional Dyspepsia).
Vericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigational[A227458,A227488] Cyclic GMP acts as a second messenger, activating a number of downstream signaling cascades that elicit a broad variety of effects, and these diverse cellular effects have implicated … [A227458] As a direct stimulator of sGC, vericiguat mitigates the need for a functional NO-sGC-cGMP axis and thereby helps to prevent the myocardial and vascular dysfunction associated with decreased sGC
Teplizumab
go.drugbank.com/drugs/DB06606ApprovedInvestigationalTeplizumab (teplizumab-mzwv) is a humanized IgG1 kappa CD3-directed monoclonal antibody used to delay the onset of type 1 diabetes (T1D). … [A241480] On November 2022, teplizumab was approved by the FDA as the first drug that can delay the onset of type 1 diabetes.
Selumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigationalMost recently, on November 20, 2025, the FDA expanded this indication to include adults [L53881] … [A193533] Following its initial FDA approval on April 10, 2020,[L49991] and Health Canada approval on August 23, 2022,[L49986] the regulatory landscape has evolved.